RU2000109265A - OBESITY TREATMENT - Google Patents
OBESITY TREATMENTInfo
- Publication number
- RU2000109265A RU2000109265A RU2000109265/04A RU2000109265A RU2000109265A RU 2000109265 A RU2000109265 A RU 2000109265A RU 2000109265/04 A RU2000109265/04 A RU 2000109265/04A RU 2000109265 A RU2000109265 A RU 2000109265A RU 2000109265 A RU2000109265 A RU 2000109265A
- Authority
- RU
- Russia
- Prior art keywords
- cys
- peptide
- arg
- group
- val
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims 3
- 235000020824 obesity Nutrition 0.000 title claims 3
- 235000001014 amino acid Nutrition 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 150000007522 mineralic acids Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- 150000007524 organic acids Chemical class 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 3
- -1 cyclic disulfide Chemical class 0.000 claims 3
- 125000000052 D-arginine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])N([H])C(N([H])[H])=N[H] 0.000 claims 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- 240000003121 Marrubium vulgare Species 0.000 claims 2
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 229960005261 Aspartic Acid Drugs 0.000 claims 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 1
- 229960002989 Glutamic Acid Drugs 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- 229960000310 ISOLEUCINE Drugs 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- VVNCNSJFMMFHPL-GSVOUGTGSA-N L-penicillamine Chemical compound CC(C)(S)[C@H](N)C(O)=O VVNCNSJFMMFHPL-GSVOUGTGSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229960003104 Ornithine Drugs 0.000 claims 1
- 229960005190 Phenylalanine Drugs 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229960001639 penicillamine Drugs 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 125000003607 serino group Chemical group [H]OC(=O)C([H])(N([H])*)C([H])([H])O[H] 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Images
Claims (15)
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe,
или соответствующую последовательность гормона роста отличного от человека млекопитающего; где в указанном аналоге
(i) аминокислоты в положениях 182 и 189 hGH соединены связью для того, чтобы способствовать образованию циклической конформации; и/или
(ii) аминокислоты в положениях 183 и 186 hGH соединены солевым мостиком или ковалентной связью;
или его соль добавления органической или неорганической кислоты.1. A peptide that includes an analog of the carboxy-terminal sequence of growth hormone, where the carboxy-terminal sequence contains amino acid residues 177-191 of human growth hormone:
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe,
or an appropriate sequence of growth hormone of a non-human mammal; where in the specified analogue
(i) the amino acids at positions 182 and 189 of the hGH are linked in order to promote cyclic conformation; and / or
(ii) the amino acids at positions 183 and 186 of hGH are connected by a salt bridge or a covalent bond;
or a salt thereof of adding an organic or inorganic acid.
Х означает положительно заряженную кислоту,
Y означает отрицательно заряженную кислоту.4. The peptide according to claim 1, where the amino acids at positions 183 and 186 are connected by a salt bridge and mean (X and Y) or (Y and X), respectively,
X means positively charged acid,
Y means negatively charged acid.
Х выбирают из группы, состоящей из L- или D-Lys и Оrn, и
Y выбирают из группы, состоящей из L- или D-Asp и Glu.7. The peptide according to claim 6, where the amino acids at positions 183 and 186 mean (X and Y) or (Y and X), respectively,
X is selected from the group consisting of L- or D-Lys and Orn, and
Y is selected from the group consisting of L- or D-Asp and Glu.
X1m-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-X2n,
где X1 и X2 выбирают каждый из группы, состоящей из L-или D-Arg, His, Lys и Тyr, и m и n означают каждый 0, 1, 2 или 3, при условии, что, по меньшей мере, m или n означает 1; его циклический дисульфид или его соль добавления органической или неорганической кислоты.8. The peptide with the sequence
X 1 m-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-X 2 n,
wherein X 1 and X 2 are each selected from the group consisting of L-or D-Arg, His, Lys, and Tyr, and m and n are each 0, 1, 2, or 3, provided that at least m or n is 1; its cyclic disulfide or its salt adding organic or inorganic acid.
Y1-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe,
где Y1 выбирают из группы, состоящей из дезаминоформы (Н), ацетильной группы (СН3СО) и других ацильных групп; его циклический дисульфид или его соль добавления органической или неорганической кислоты.9. The peptide with the sequence
Y 1 -Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe,
where Y 1 is selected from the group consisting of desaminoform (H), acetyl group (CH 3 CO) and other acyl groups; its cyclic disulfide or its salt adding organic or inorganic acid.
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-Y2,
где Y2 выбирают из группы CONH2 и алкиламидных групп; его циклический дисульфид или его соль добавления органической или неорганической кислоты.10. The peptide with the sequence
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-Y 2 ,
where Y 2 selected from the group CONH 2 and alkylamide groups; its cyclic disulfide or its salt adding organic or inorganic acid.
где использованная аббревиатура аминокислотных остатков находится в соответствии со стандартной пептидной номенклатурой, а именно:
Gly = глицин - Ilе = изолейцин
Glu = глутаминовая кислота - Phe = фенилаланин
Cys = цистеин - Arg = аргинин
Gln = глутамин - Leu = лейцин
Sеr = серин - Val = валин
Lys = лизин - Alа = аланин
Asp = аспарагиновая кислота - His = гистидин
Оrn = орнитин - Тyr = тирозин
Pen = пеницилламин (β,β-диметилцистеин)
где все аминокислоты, за исключением глицина, имеют абсолютную L-конфигурацию, если не указана D-конфигурация, и пептид содержит подходящую циклическую дисульфидную связь между Сys(182) и Сys(189) или Pen(182) и Pen(189), или его соль добавления неорганической или органической кислоты.11. The peptide that is selected from the group consisting of a sequence (see graphic part),
where the abbreviation used for amino acid residues is in accordance with the standard peptide nomenclature, namely:
Gly = glycine - Ilе = isoleucine
Glu = glutamic acid - Phe = phenylalanine
Cys = cysteine - Arg = arginine
Gln = Glutamine - Leu = Leucine
Ser = Serine - Val = Valine
Lys = lysine - Ala = alanine
Asp = Aspartic Acid - His = Histidine
Orn = Ornithine - Tyr = Tyrosine
Pen = penicillamine (β, β-dimethylcysteine)
where all amino acids, with the exception of glycine, have an absolute L configuration, unless a D configuration is indicated, and the peptide contains a suitable cyclic disulfide bond between Cys (182) and Cys (189) or Pen (182) and Pen (189), or its salt is the addition of an inorganic or organic acid.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO9001A AUPO900197A0 (en) | 1997-09-08 | 1997-09-08 | Treatment of obesity |
| AUPO9001 | 1997-09-08 | ||
| AUPP0398 | 1997-11-13 | ||
| AUPP0398A AUPP039897A0 (en) | 1997-11-13 | 1997-11-13 | Treatment of obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000109265A true RU2000109265A (en) | 2002-03-10 |
| RU2223970C2 RU2223970C2 (en) | 2004-02-20 |
Family
ID=25645599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000109265/04A RU2223970C2 (en) | 1997-09-08 | 1998-09-04 | Obesity treatment |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6737407B1 (en) |
| EP (1) | EP1012189B1 (en) |
| JP (1) | JP4334761B2 (en) |
| CN (1) | CN1195776C (en) |
| AT (1) | ATE377026T1 (en) |
| BR (1) | BR9811755A (en) |
| CA (1) | CA2303395C (en) |
| DE (1) | DE69838647T2 (en) |
| ES (1) | ES2296342T3 (en) |
| NZ (1) | NZ502993A (en) |
| RU (1) | RU2223970C2 (en) |
| WO (1) | WO1999012969A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ387599A0 (en) | 1999-11-05 | 1999-12-02 | Metabolic Pharmaceuticals Limited | Product and method for control of obesity |
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| GB0315182D0 (en) * | 2003-06-28 | 2003-08-06 | Asterion Ltd | Cytokine variant polypeptides |
| WO2005007859A2 (en) * | 2003-07-11 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2005105132A1 (en) * | 2004-05-04 | 2005-11-10 | Metabolic Pharmaceuticals Limited | Methods for preventing or treating bone disorders |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| ES2258923B1 (en) * | 2005-02-23 | 2007-11-01 | Universitat De Les Illes Balears | USE OF LEPTINE FOR THE PREVENTION OF EXCESS OF BODY WEIGHT AND COMPOSITION CONTAINING LEPTINE. |
| WO2007014432A1 (en) * | 2005-08-02 | 2007-02-08 | Metabolic Pharmaceuticals Limited | Peptide conjugate for oral delivery of hydrophilic peptide analgesics |
| WO2007068039A1 (en) * | 2005-12-12 | 2007-06-21 | Metabolic Pharmaceuticals Limited | Treatment of weight gain in estrogen deficient mammals |
| EP2118080B1 (en) | 2007-02-09 | 2016-08-31 | Ocera Therapeutics, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
| WO2008098280A1 (en) * | 2007-02-16 | 2008-08-21 | Polychip Pharmaceuticals Pty Ltd | Methods for the synthesis of dicarba bridges in growth hormone peptides |
| EP2350118B1 (en) | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| WO2010033215A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of aod-like peptides |
| JP6363952B2 (en) | 2011-12-09 | 2018-07-25 | メタボリック、ファーマシューティカルズ、プロプライエタリー、リミテッドＭｅｔａｂｏｌｉｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｐｔｙ Ｌｔｄ | Use of growth hormone fragments |
| CN102827290A (en) * | 2012-09-07 | 2012-12-19 | 浙江大学 | Fusion protein of human serum albumin and lipolysis structural domain of human growth hormone |
| GB2507341A (en) * | 2012-10-29 | 2014-04-30 | Peter Kenny | Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone |
| KR20200130681A (en) * | 2018-01-15 | 2020-11-19 | 레터럴 아이피 피티와이 리미티드 | Peptides and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG49718A3 (en) | 1983-07-15 | 1992-01-15 | Bio Technology General Corp | Method for preparing of polypeptid with superoxiddismutasne activitty |
| US4863901A (en) | 1986-01-09 | 1989-09-05 | Brigham & Women's Hospital | Use of growth hormone for nitrogen retention under hypocaloric conditions |
| US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| US5126324A (en) | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| AU693478B2 (en) | 1994-11-10 | 1998-07-02 | Metabolic Pharmaceuticals Limited | Treatment of obesity |
-
1998
- 1998-09-04 NZ NZ502993A patent/NZ502993A/en not_active IP Right Cessation
- 1998-09-04 US US09/508,054 patent/US6737407B1/en not_active Expired - Lifetime
- 1998-09-04 JP JP2000510774A patent/JP4334761B2/en not_active Expired - Fee Related
- 1998-09-04 WO PCT/AU1998/000724 patent/WO1999012969A1/en active IP Right Grant
- 1998-09-04 DE DE69838647T patent/DE69838647T2/en not_active Expired - Lifetime
- 1998-09-04 CA CA002303395A patent/CA2303395C/en not_active Expired - Lifetime
- 1998-09-04 RU RU2000109265/04A patent/RU2223970C2/en active
- 1998-09-04 EP EP98941152A patent/EP1012189B1/en not_active Expired - Lifetime
- 1998-09-04 ES ES98941152T patent/ES2296342T3/en not_active Expired - Lifetime
- 1998-09-04 BR BR9811755-6A patent/BR9811755A/en not_active Application Discontinuation
- 1998-09-04 AT AT98941152T patent/ATE377026T1/en not_active IP Right Cessation
- 1998-09-04 CN CNB988100894A patent/CN1195776C/en not_active Expired - Lifetime
-
2004
- 2004-05-11 US US10/842,485 patent/US20040192608A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2000109265A (en) | OBESITY TREATMENT | |
| RU2223970C2 (en) | Obesity treatment | |
| Hruby et al. | . alpha.-Melanotropin: the minimal active sequence in the frog skin bioassay | |
| US6320024B1 (en) | Method for design of substances that enhance memory and improve the quality of life | |
| US4350627A (en) | Biologically active peptides | |
| CA1241643A (en) | Peptides affecting the immune regulation and a process for their preparation | |
| CN1031242C (en) | Linear and cyclic analogues of alpha-MSH fragments with extraordinary potency | |
| Chen et al. | Structure–bioactivity of C‐terminal pentapeptide of osteogenic growth peptide [OGP (10–14)] | |
| Altmann et al. | Confromational Studies on Peptides Containing Enantiometric α‐Methyl α‐Amino Acids. Part I. Differential conformational properties of (R)‐and (S)‐2‐methylaspartic acid | |
| US7220725B2 (en) | Pharmaceutical composition comprising an analgesic peptide and method for treating pain | |
| WO1997015593A1 (en) | Neurotrophin antagonists | |
| US5079231A (en) | Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them | |
| US5955421A (en) | Peptides containing D-2-alkyl-Tryptophan | |
| EP0783521A1 (en) | Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone | |
| JP3621099B2 (en) | Osteogenic growth oligopeptide and pharmaceutical composition containing the same | |
| JP2000507925A (en) | Synthetic and pseudopeptides having osteogenic activity and pharmaceutical preparations containing them | |
| AU2001280052A1 (en) | Pharmaceutical composition comprising an analgesic peptide | |
| US5039790A (en) | Bioactive fragment of interleukin-1-B that has antagonistic activity | |
| CA1157466A (en) | Peptides having thymopoietin-like activity | |
| HU205143B (en) | Process for producing peptides having t cell suppressor activity and pharmaceutical compositions comprising same | |
| US8063016B2 (en) | Retro-inverso peptides derived from interleukin-6 | |
| RU95120588A (en) | CYCLOGEXAEPEPTIDES, THEIR MIXTURES, METHOD FOR PRODUCING AND USING THEM | |
| Hirotsu et al. | Stereoisomers of luteinizing hormone-releasing hormone | |
| RU2008129731A (en) | NEW PEPTIDES-T-HELPER ANTIGENIC DETERMINANTS (THD) | |
| US5225400A (en) | Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them |